PARIS--(BUSINESS WIRE)--Regulatory News: Ipsen (Euronext: FR0010259150; Paris: IPN) today announced the start of the filing process in Europe of the 6-month sustained release formulation of Decapeptyl®, a luteinizing hormone releasing hormone agonist (LHRHa) developed by Debiopharm for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.
